About Avextra
Avextra is a company based in Berlin (Germany) founded in 2004 by Bernhard Babylon and David Reckeweg Lecompte. Avextra has raised $48.08 million across 4 funding rounds from investors including Fastforward Innovations and Iberis Capital. Avextra offers products and services including THC/CBD Quick Test and Cannabis Extract. Avextra operates in a competitive market with competitors including Tilray, iuvo Therapeutics, Canobo, LIO Pharmaceuticals and enua Pharma, among others.
- Headquarter Berlin, Germany
- Founders Bernhard Babylon, David Reckeweg Lecompte
-
Sectors
HealthcareConsumer
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avextra Pharma Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$48.08 M (USD)
in 4 rounds
-
Latest Funding Round
$21.49 M (USD), Series B
Feb 07, 2024
-
Investors
Fastforward Innovations
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Avextra
Avextra offers a comprehensive portfolio of products and services, including THC/CBD Quick Test and Cannabis Extract.
Rapid test kit for detecting THC and CBD levels in samples
Standardized extract for medical treatments and therapies
Funding Insights of Avextra
Avextra has successfully raised a total of $48.08M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $21.49 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Avextra
Avextra has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Fastforward Innovations and Iberis Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Iberis Capital is recognized as a leading private equity and venture capital manager in Portugal.
|
Locked | Locked | Locked | |
|
Tech & life Science focused early stage VC firm investing in North America & Europe
|
Locked | Locked | Locked |
Investor details for Avextra
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avextra
Investment portfolio details for Avextra
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avextra
Detailed financials for Avextra
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avextra Comparisons
Peer comparison for Avextra
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avextra
Avextra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tilray, iuvo Therapeutics, Canobo, LIO Pharmaceuticals and enua Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Online e-distributor offering cannabis products for medical purposes
|
|
| Locked | Locked | Locked |
Licensed cannabis products are imported and wholesaled under pharmaceutical standards.
|
|
| Locked | Locked | Locked |
Offers high-quality CBD oils, gels, and hemp products through online sales and retail channels.
|
|
| Locked | Locked | Locked |
CRO focused on providing cannabis clinical trial supply & training services
|
|
| Locked | Locked | Locked |
Provides certified medical cannabis products to patients, pharmacies, and doctors in Germany.
|
Detailed competitors of Avextra
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avextra
Complete news archive for Avextra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avextra
Avextra was founded in 2004 and raised its 1st funding round 17 years after it was founded.
Avextra is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Bernhard Babylon is the current CEO of Avextra. They have also founded this company.
Avextra is a funded company, having raised a total of $48.08M across 4 funding rounds to date.
Avextra was founded in 2004 in Berlin, Germany, where research and development services for medicinal cannabis products are conducted. Operations center on the medicinal cannabis sector, with expertise applied to product formulation and testing. The company is co-led by Bernhard Babylon and David Reckeweg Lecompte as co-founders and co-CEOs. Services are tailored for pharmaceutical and therapeutic applications in the European market.
Avextra's top competitors include Tilray, iuvo Therapeutics and LIO Pharmaceuticals.
Avextra offers THC/CBD Quick Test and Cannabis Extract.
Avextra has 2 investors. Key investors include Fastforward Innovations, and Iberis Capital.